Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - 21st Century Oncology Holdings, Inc. | a16-18682_110q.htm |
| EX-32.2 - EX-32.2 - 21st Century Oncology Holdings, Inc. | a16-18682_1ex32d2.htm |
| EX-32.1 - EX-32.1 - 21st Century Oncology Holdings, Inc. | a16-18682_1ex32d1.htm |
| EX-31.2 - EX-31.2 - 21st Century Oncology Holdings, Inc. | a16-18682_1ex31d2.htm |
| EX-31.1 - EX-31.1 - 21st Century Oncology Holdings, Inc. | a16-18682_1ex31d1.htm |
Exhibit 99.1
Supplemental Financial Information
21st Century Oncology, Inc. (21C), a subsidiary of the Company, has payment obligations under the senior secured credit facility, and Senior Notes that are guaranteed by the Company. The Company owns 100% of 21C and certain domestic subsidiaries of 21C, all of which are, directly or indirectly, 100% owned by 21C (the “Subsidiary Guarantors” and, collectively with the Company, the “Guarantors”). Such guarantees are full, unconditional and joint and several. The consolidated joint ventures, foreign subsidiaries and professional corporations of the Company are non-guarantors. The following supplemental financial information sets forth, on an unconsolidated basis, selected balance sheet accounts, revenues and adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) information.
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
March 31, 2016
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Balance Sheets Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
As of March 31, 2016 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
Cash |
|
47,774 |
|
24,629 |
|
— |
|
72,403 |
|
|
Current assets (excluding cash) |
|
143,251 |
|
46,055 |
|
(10,099 |
) |
179,207 |
|
|
Long-term assets |
|
928,664 |
|
156,270 |
|
(191,069 |
) |
893,865 |
|
|
Total Assets |
|
1,119,689 |
|
226,954 |
|
(201,168 |
) |
1,145,475 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
Current portion of debt |
|
1,090,728 |
|
3,338 |
|
— |
|
1,094,066 |
|
|
Current liabilities (excluding debt) |
|
163,103 |
|
19,524 |
|
(7,584 |
) |
175,043 |
|
|
Long-term debt, less current portion |
|
29,952 |
|
4,055 |
|
— |
|
34,007 |
|
|
Long-term liabilities (excluding debt) |
|
144,520 |
|
47,427 |
|
(82,915 |
) |
109,032 |
|
|
Total Liabilities |
|
1,428,303 |
|
74,344 |
|
(90,499 |
) |
1,412,148 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, 2016 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
216,749 |
|
67,918 |
|
(14,369 |
) |
270,298 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
44,394 |
|
8,043 |
|
(3,614 |
) |
48,823 |
|
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(3,614 |
) |
— |
|
3,614 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
1,796 |
|
— |
|
1,796 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(214 |
) |
— |
|
(214 |
) |
|
Gain on the contribution of a radiation facility to a joint venture |
|
(12,629 |
) |
— |
|
— |
|
(12,629 |
) |
|
Fair value adjustment of earn-out liabilities |
|
1 |
|
— |
|
— |
|
1 |
|
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
(2,535 |
) |
— |
|
— |
|
(2,535 |
) |
|
Other expenses |
|
1,670 |
|
33 |
|
— |
|
1,703 |
|
|
Non-cash expenses |
|
757 |
|
83 |
|
— |
|
840 |
|
|
Sale-lease back adjustments |
|
(289 |
) |
— |
|
— |
|
(289 |
) |
|
Acquisition-related costs |
|
623 |
|
9 |
|
— |
|
632 |
|
|
Litigation matters |
|
866 |
|
— |
|
— |
|
866 |
|
|
Sub-total |
|
29,244 |
|
9,750 |
|
— |
|
38,994 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
6,679 |
|
(6,679 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
35,923 |
|
3,071 |
|
— |
|
38,994 |
|
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
March 31, 2015
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Balance Sheets Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
As of December 31, 2015 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
Cash |
|
48,336 |
|
16,875 |
|
— |
|
65,211 |
|
|
Current assets (excluding cash) |
|
121,775 |
|
44,283 |
|
(9,992 |
) |
156,066 |
|
|
Long-term assets |
|
895,264 |
|
170,023 |
|
(182,703 |
) |
882,584 |
|
|
Total Assets |
|
1,065,375 |
|
231,181 |
|
(192,695 |
) |
1,103,861 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
Current portion of debt |
|
1,020,343 |
|
3,534 |
|
— |
|
1,023,877 |
|
|
Current liabilities (excluding debt) |
|
169,946 |
|
28,556 |
|
(9,912 |
) |
188,590 |
|
|
Long-term debt, less current portion |
|
43,728 |
|
5,505 |
|
— |
|
49,233 |
|
|
Long-term liabilities (excluding debt) |
|
138,867 |
|
44,104 |
|
(74,927 |
) |
108,044 |
|
|
Total Liabilities |
|
1,372,884 |
|
81,699 |
|
(84,839 |
) |
1,369,744 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, 2015 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
177,383 |
|
118,226 |
|
(19,976 |
) |
275,633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
22,678 |
|
11,721 |
|
(1,314 |
) |
33,085 |
|
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(1,314 |
) |
— |
|
1,314 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
2,259 |
|
— |
|
2,259 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(964 |
) |
— |
|
(964 |
) |
|
Fair value adjustment of earn-out liabilities |
|
232 |
|
228 |
|
— |
|
460 |
|
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
1,693 |
|
— |
|
— |
|
1,693 |
|
|
Other expenses |
|
1,884 |
|
53 |
|
— |
|
1,937 |
|
|
Non-cash expenses |
|
808 |
|
203 |
|
— |
|
1,011 |
|
|
Sale-lease back adjustments |
|
(449 |
) |
— |
|
— |
|
(449 |
) |
|
Acquisition-related costs |
|
1,251 |
|
59 |
|
— |
|
1,310 |
|
|
Litigation matters |
|
1,941 |
|
— |
|
— |
|
1,941 |
|
|
Sub-total |
|
28,724 |
|
13,559 |
|
— |
|
42,283 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
9,310 |
|
(9,310 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
38,034 |
|
4,249 |
|
— |
|
42,283 |
|